Travere Therapeutics, Inc. (TVTX)Healthcare | Biotechnology | San Diego, United States | NasdaqGM
40.77 USD
+1.23
(3.111%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 40.97 +0.20 (0.491%) ⇧ (April 17, 2026, 7:51 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:54 p.m. EDT
TVTX is a high-risk, high-reward biotech stock with a recent pullback and insider selling, which could indicate caution. The short-term forecast shows a small positive movement, but the long-term fundamentals are weak, with negative profit margins and a high debt-to-equity ratio. The lack of dividends and the recent insider activity suggest that investors should be cautious. While there is some bullish speculation in the options market, the overall picture is mixed, and the stock is not a strong buy at this time. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.067736 |
| AutoARIMA | 0.067736 |
| MSTL | 0.069894 |
| AutoTheta | 0.081190 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 17% |
| H-stat | 9.62 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.66 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 286.283 |
| Revenue per Share | 5.501 |
| Market Cap | 3,765,917,184 |
| Forward P/E | 8.94 |
| Beta | 0.87 |
| Profit Margins | -5.21% |
| Previous Name | Retrophin, Inc. |
| Website | https://travere.com |
As of April 11, 2026, 3:54 p.m. EDT: The options activity indicates mixed sentiment. The calls show a concentration of open interest and volume around strikes above the current price, suggesting some bullish speculation, especially around the $35 and $50 strikes. However, the puts also show significant open interest around strikes below the current price, indicating potential bearish sentiment. The IV (implied volatility) is generally low, suggesting market participants are not overly concerned about large price swings in the near term. The overall options data suggests a cautious approach with some potential for upward movement, but also some risk of downward pressure.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.6982131 |
| Address1 | 3,611 Valley Centre Drive |
| Address2 | Suite 300 |
| All Time High | 43.31 |
| All Time Low | 1.5 |
| Ask | 40.89 |
| Ask Size | 12 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 3,838,580 |
| Average Daily Volume3 Month | 1,816,745 |
| Average Volume | 1,816,745 |
| Average Volume10Days | 3,838,580 |
| Beta | 0.868 |
| Bid | 40.66 |
| Bid Size | 6 |
| Board Risk | 1 |
| Book Value | 1.263 |
| City | San Diego |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 6 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 40.77 |
| Current Ratio | 2.736 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 40.88 |
| Day Low | 38.67 |
| Debt To Equity | 286.283 |
| Display Name | Travere Therapeutics |
| Earnings Call Timestamp End | 1,771,536,600 |
| Earnings Call Timestamp Start | 1,771,536,600 |
| Earnings Timestamp | 1,771,534,800 |
| Earnings Timestamp End | 1,777,579,200 |
| Earnings Timestamp Start | 1,777,579,200 |
| Ebitda | -2,081,000 |
| Ebitda Margins | -0.00424 |
| Enterprise To Ebitda | -1,810.007 |
| Enterprise To Revenue | 7.676 |
| Enterprise Value | 3,766,625,024 |
| Eps Current Year | 1.56714 |
| Eps Forward | 4.55857 |
| Eps Trailing Twelve Months | -0.57 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.0084 |
| Fifty Day Average Change | 10.7616005 |
| Fifty Day Average Change Percent | 0.3586196 |
| Fifty Two Week Change Percent | 169.8213 |
| Fifty Two Week High | 43.31 |
| Fifty Two Week High Change | -2.540001 |
| Fifty Two Week High Change Percent | -0.058646984 |
| Fifty Two Week Low | 13.88 |
| Fifty Two Week Low Change | 26.89 |
| Fifty Two Week Low Change Percent | 1.9373199 |
| Fifty Two Week Range | 13.88 - 43.31 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,352,385,000,000 |
| Float Shares | 91,227,815 |
| Forward Eps | 4.55857 |
| Forward P E | 8.943594 |
| Free Cashflow | -38,295,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 497 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.55912 |
| Gross Profits | 274,377,984 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0076800003 |
| Held Percent Institutions | 1.1581199 |
| Implied Shares Outstanding | 92,369,812 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. Its clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase, a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a collaboration agreement with PharmaKrysto Limited for the pre-clinical activities associated with the cystinuria program. Travere Therapeutics, Inc. was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. The company is headquartered in San Diego, California. |
| Long Name | Travere Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 3,765,917,184 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_133551169 |
| Most Recent Quarter | 1,767,139,200 |
| Name Change Date | 2,026-04-18 |
| Net Income To Common | -50,261,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 3,765,917,235 |
| Number Of Analyst Opinions | 14 |
| Open | 40.268 |
| Operating Cashflow | 37,784,000 |
| Operating Margins | -0.25004 |
| Overall Risk | 3 |
| Payout Ratio | 0.0 |
| Phone | 888 969 7879 |
| Post Market Change | 0.20000076 |
| Post Market Change Percent | 0.49055865 |
| Post Market Price | 40.97 |
| Post Market Time | 1,776,469,887 |
| Prev Name | Retrophin, Inc. |
| Previous Close | 39.54 |
| Price Eps Current Year | 26.015545 |
| Price Hint | 2 |
| Price To Book | 32.280285 |
| Price To Sales Trailing12 Months | 7.674144 |
| Profit Margins | -0.052059997 |
| Quick Ratio | 2.528 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | 1.23 |
| Regular Market Change Percent | 3.11077 |
| Regular Market Day High | 40.88 |
| Regular Market Day Low | 38.67 |
| Regular Market Day Range | 38.67 - 40.88 |
| Regular Market Open | 40.268 |
| Regular Market Previous Close | 39.54 |
| Regular Market Price | 40.77 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,922,617 |
| Return On Assets | -0.06548 |
| Return On Equity | -0.57803 |
| Revenue Growth | 0.734 |
| Revenue Per Share | 5.501 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 3 |
| Shares Outstanding | 92,369,812 |
| Shares Percent Shares Out | 0.1456 |
| Shares Short | 13,446,405 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 14,180,739 |
| Short Name | Travere Therapeutics, Inc. |
| Short Percent Of Float | 0.1907 |
| Short Ratio | 10.89 |
| Source Interval | 15 |
| State | CA |
| Symbol | TVTX |
| Target High Price | 56.0 |
| Target Low Price | 40.0 |
| Target Mean Price | 48.21429 |
| Target Median Price | 49.0 |
| Total Cash | 322,796,000 |
| Total Cash Per Share | 3.499 |
| Total Debt | 328,732,992 |
| Total Revenue | 490,728,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.57 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 27.522875 |
| Two Hundred Day Average Change | 13.247126 |
| Two Hundred Day Average Change Percent | 0.4813133 |
| Type Disp | Equity |
| Volume | 1,922,617 |
| Website | https://travere.com |
| Zip | 92,130 |